Applied Filters
Australian bid for OxyContin generic dismissed
The Federal Court of Australia has dismissed Spirit Pharmaceutical’s bid to introduce a generic version of painkiller OxyContin.
IPAB sets aside Sutent patent rejection
India’s Intellectual Property Appellate Board has set aside a decision revoking a Pfizer-licensed patent directed to cancer drug Sutent.
Amgen and Astellas join forces in Japan
California-based biotechnology company Amgen has entered into a long-term partnership with Japanese pharmaceutical company Astellas Pharmas Inc to provide new medicines in Japan.
Mylan signs generic truce with Shionogi and Andrx
Generic drug maker Mylan has struck a deal with pharma companies Shionogi and Andrx to resolve a patent dispute over their diabetes drug Fortamet.
Australian Myriad ruling to face appeal
Law firm Maurice Blackburn revealed on Monday that it will appeal against an Australian court decision that backed Myriad Genetics’ ownership of a human gene mutation linked to breast cancer.
BRICK nations catching up on patents, as Brazil looks to life sciences
In a report published by Thomson Reuters on February 20, the BRICK nations were shown to be filing almost as many patents as the G7 nations in 2011.
Australian court backs Myriad in human gene patent dispute
A judge at Australia’s Federal Court has upheld Myriad Genetics’ patent covering a human gene mutation linked to breast cancer, in the country’s first court ruling on whether isolated genes can be patented.
